menu
    • menu
    [{"orgOrder":0,"company":"Chang Gung Memorial Hospital","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Chang Gung Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Chang Gung Memorial Hospital \/ TTY BIOPHARM CO LTD","highestDevelopmentStatusID":"11","companyTruncated":"Chang Gung Memorial Hospital \/ TTY BIOPHARM CO LTD"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"TTY BIOPHARM CO LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TTY BIOPHARM CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"Tecnoquimicas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"COLOMBIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Tecnoquimicas","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tecnoquimicas \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Tecnoquimicas \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Sodium Alginate

    Menu

    Sodium Alginate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tecnoquimicas

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tecnoquimicas

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of Magaldrate

                            Details : Sodium Alginate is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 16, 2024

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Reckitt Benckiser

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study

                            Details : Sodium Alginate is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroesophageal Reflux.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 07, 2015

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Reckitt Benckiser

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients

                            Details : Sodium Alginate is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroesophageal Reflux.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 02, 2015

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Chang Gung Memorial Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chang Gung Memorial Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : TTY BIOPHARM CO LTD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturba...

                            Details : Sodium Alginate is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gastroesophageal Reflux.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 29, 2014

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : TTY BIOPHARM CO LTD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Reckitt Benckiser

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients

                            Details : Sodium Alginate is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroesophageal Reflux.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 07, 2013

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Reckitt Benckiser

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

                            Details : Sodium Alginate is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroesophageal Reflux.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 05, 2013

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TTY BIOPHARM CO LTD

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TTY BIOPHARM CO LTD

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux

                            Details : Sodium Alginate is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Laryngopharyngeal Reflux.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 12, 2011

                            Lead Product(s) : Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth